On October 14, 2022, the CCI dismissed a complaint filed by one
Mr. Pinesh S. Doriwala (‘Informant')
against Sanofi India Limited
(‘Sanofi') alleging anti-competitive
conduct in contravention of Section 3(4)(d) of the Competition
Act.1
The Informant is a partner in Shri Shriman Narayan Rahat Dava
Centre (‘SSNRDC'), a firm that deals
in pharmaceutical products at a special discount rate of 20%-35% of
the Maximum Retail Price (‘MRP') for
Indian Army, senior citizens, disabled individuals and NRIs and
others. SSNRDC delivers pharmaceutical products at doorsteps
without any advance payment.
Sanofi is primarily engaged in the business of manufacturing and
trading of pharmaceutical products of leading brands in therapeutic
uses for diabetes, cardiology, thrombosis, antihistamines, and
central nervous system to the consumers in India.